臨床試驗

Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction

NCT：NCT07415330 · NOT_YET_RECRUITING

NCT IDNCT07415330

狀態NOT_YET_RECRUITING

開始日期2026-07-20

完成時間2026-09-01

SponsorDemaod Ltd (INDUSTRY)

First posted2026-02-17

Last updated2026-05-12

簡要摘要

This is a prospective, multi-center, randomized, sham-controlled clinical investigation designed to evaluate the safety and effectiveness of the Lacrima VR system in adult subjects with Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD). Subjects will be randomized in a 1:1 ratio to receive either active Lacrima VR treatment or a sham device with reduced luminance. Effectiveness will be assessed primarily by change in Tear Break-Up Time (TBUT), and safety will be evaluated by the incidence of device-related adverse events.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。